64 related articles for article (PubMed ID: 27376361)
21. Emerging Factors Implicated in Fibrotic Organ-Associated Thrombosis: The Case of Two Organs.
Leiva O; Bekendam RH; Garcia BD; Thompson C; Cantor A; Chitalia V; Ravid K
TH Open; 2019 Apr; 3(2):e165-e170. PubMed ID: 31259299
[TBL] [Abstract][Full Text] [Related]
22. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA
BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359
[TBL] [Abstract][Full Text] [Related]
23. SDF1α-induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K/AKT, PLCγ1 and RhoA.
Nimmagadda SC; Frey S; Müller P; Wolleschak D; Weinert S; Keller U; Edelmann B; Fischer T
Haematologica; 2019 Jul; 104(7):e288-e292. PubMed ID: 30765477
[No Abstract] [Full Text] [Related]
24. Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.
Merlinsky TR; Levine RL; Pronier E
Clin Cancer Res; 2019 May; 25(10):2956-2962. PubMed ID: 30655313
[TBL] [Abstract][Full Text] [Related]
25. The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms.
Greenfield G; McPherson S; Mills K; McMullin MF
J Transl Med; 2018 Dec; 16(1):360. PubMed ID: 30558676
[TBL] [Abstract][Full Text] [Related]
26. Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature.
Zhou A; Afzal A; Oh ST
Curr Hematol Malig Rep; 2017 Oct; 12(5):397-405. PubMed ID: 28948488
[TBL] [Abstract][Full Text] [Related]
27. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.
Kc D; Falchi L; Verstovsek S
Ann Hematol; 2017 Oct; 96(10):1595-1604. PubMed ID: 28808761
[TBL] [Abstract][Full Text] [Related]
28. Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2
Saki N; Shirzad R; Rahim F; Saki Malehi A
Clin Transl Oncol; 2017 Jul; 19(7):874-883. PubMed ID: 28205126
[TBL] [Abstract][Full Text] [Related]
29. Re: Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis.
Kourie HR; Ameye L; Paesmans M; Bron D
Ann Hematol; 2016 Dec; 95(12):2105-2106. PubMed ID: 27686082
[No Abstract] [Full Text] [Related]
30. Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.
Kourie HR; Ameye L; Paesmans M; Bron D
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):264-8. PubMed ID: 26935576
[TBL] [Abstract][Full Text] [Related]
31. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
Rumi E; Pietra D; Pascutto C; Guglielmelli P; Martínez-Trillos A; Casetti I; Colomer D; Pieri L; Pratcorona M; Rotunno G; Sant'Antonio E; Bellini M; Cavalloni C; Mannarelli C; Milanesi C; Boveri E; Ferretti V; Astori C; Rosti V; Cervantes F; Barosi G; Vannucchi AM; Cazzola M;
Blood; 2014 Aug; 124(7):1062-9. PubMed ID: 24986690
[TBL] [Abstract][Full Text] [Related]
32. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.
Misawa K; Yasuda H; Araki M; Ochiai T; Morishita S; Shirane S; Edahiro Y; Gotoh A; Ohsaka A; Komatsu N
Int J Hematol; 2018 Jun; 107(6):673-680. PubMed ID: 29464483
[TBL] [Abstract][Full Text] [Related]
33. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis.
Pei YQ; Wu Y; Wang F; Cui W
Ann Hematol; 2016 Sep; 95(9):1391-8. PubMed ID: 27376361
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]